Hybrid Assistive Limb Application in Multiple Sclerosis Patients
NCT: NCT07326852 · COMPLETED
Brief Summary
The Hybrid Assistive Limb (HAL) exoskeleton detects bioelectrical signals from the muscles, responds to the intention of voluntary movement, and provides biological feedback. In this study, the effects of HAL application on walking performance and balance in patients with multiple sclerosis will be examined in a single-center, controlled design. Participants will undergo walking rehabilitation with HAL for 1 hour per day, 5 days a week, for a total of 2 months. Walking and balance performance will be assessed before and after the intervention using the 10-Minute Walk Test (10MWT) to measure maximum walking speed, the 6-Minute Walk Test (6MWT) to evaluate walking endurance and cardiorespiratory performance, and the Timed Up and Go Test (TUG) to assess functional mobility and dynamic balance. Additionally, walking parameters and static balance will be measured using Tecnobody systems. Appropriate statistical tests will be applied, and a significance level of p\<0.05 will be considered.
Frequently Asked Questions
What is Hybrid Assistive Limb Application in Multiple Sclerosis Patients?
Hybrid Assistive Limb Application in Multiple Sclerosis Patients is a clinical trial registered under NCT07326852. Current status: COMPLETED.
What is the status of NCT07326852?
The current status of NCT07326852 (Hybrid Assistive Limb Application in Multiple Sclerosis Patients) is: COMPLETED.
When did Hybrid Assistive Limb Application in Multiple Sclerosis Patients start?
Hybrid Assistive Limb Application in Multiple Sclerosis Patients started on 2025-10-08.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.